



300 NW 70th Avenue, Suite 102 • Plantation, Florida 33317
(954) 723-0057 Phone • (954) 723-0353 Fax
email: info@naceonline.com

**Clinical Updates for
Nurse Practitioners and
Physician Assistants: 2012/2013**



**January 19, 2013
Crowne Plaza Jacksonville Riverfront
Jacksonville, FL**

**Course Directors
Deborah Paschal, CRNP
Gregg Sherman, MD**

**Activity Director
Michelle Frisch, MPH, CCMEP**

**Program Evaluation
February 5, 2013**

In January 2013, the National Association for Continuing Education (NACE) sponsored a CE activity, *Clinical Updates for Nurse Practitioners and Physician Assistants: 2012/2013*, in Jacksonville, FL

This educational activity was designed to provide nurse practitioners and physician assistants the opportunity to learn about Osteoporosis, Psoriasis, Inflammatory Bowel Disease, Diabetes, Opioid Analgesics, and Atrial Fibrillation.

In planning this CE activity, NACE performed a needs assessment. A literature search was conducted, national guidelines were reviewed, survey data was analyzed, and experts in each therapeutic area were consulted to determine gaps in practitioner knowledge, competence or performance.

Seventy six healthcare practitioners registered to attend *Clinical Updates for Nurse Practitioners and Physician Assistants: 2012/2013*, in Jacksonville, FL. Forty seven healthcare practitioners actually attended this conference. Each attendee was asked to complete and return an activity evaluation form prior to the end of the conference. Forty seven completed forms were received. The data collected is displayed in this report.

CME ACCREDITATION

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 6.5 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society.


Physician assistants may receive a maximum of 6.5 hours of Category 1 credit for completing this program.

This program is approved for 6.5 contact hours of continuing education (which includes 5.5 hours of pharmacology) by the American Academy of Nurse Practitioners. Program ID 1210364

This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.


What is your professional degree?

Label	Frequency	Percent	Valid Percent
MD	2	4.26	4.26
DO	0	0.00	0.00
NP	30	63.83	63.83
PA	13	27.66	27.66
RN	1	2.13	2.13
Other	1	2.13	2.13
Total Valid	47	100.00	100.00




What is your specialty?

Label	Frequency	Percent	Valid Percent
Primary Care	33	70.21	70.21
Endocrinology	1	2.13	2.13
Rheumatology	2	4.26	4.26
Pulmonology	0	0.00	0.00
Cardiology	2	4.26	4.26
Gastroenterology	1	2.13	2.13
OB/GYN	0	0.00	0.00
Other	8	17.02	17.02
Total Valid	47	100.00	100.00




Upon completion of this activity, I can now - Identify appropriate candidates for BMD testing incorporating the FRAX 10-year fracture risk into treatment decisions; initiate pharmacologic therapy for patients who meet NOF guideline recommendations for pharmacologic management; implement education for dietary and supplemental calcium and vitamin D and exercises to prevent osteoporosis and related fractures; and recognize and overcome barriers to adherence and effectiveness of osteoporosis therapy:

Label	Frequency	Percent	Valid Percent
Yes	42	89.36	91.30
Somewhat	4	8.51	8.70
Not at all	0	0.00	0.00
Total Valid	46	97.87	100.00
Total Missing	1	2.13	
Total	47	100.00	




Upon completion of this activity, I can now - Explain the current pathophysiologic mechanisms associated with the development of psoriatic disease; discuss the impact of psoriatic disease including its effects on mood, cardiovascular risk, quality of life, and other co-morbid conditions; recognize the percent of body surface area that categorizes a patient for topical or systemic therapy; and implement appropriate treatment plans for patients who are candidates for topical and/or systemic therapy:

Label	Frequency	Percent	Valid Percent
Yes	34	72.34	73.91
Somewhat	11	23.40	23.91
Not at all	1	2.13	2.17
Total Valid	46	97.87	100.00
Total Missing	1	2.13	
Total	47	100.00	




Upon completion of this activity, I can now - Identify the conditions referred to as inflammatory bowel disease (IBD), and discuss their clinical presentations; implement appropriate pharmacologic and nonpharmacologic therapeutic strategies for managing IBD in accordance with evidence-based guidelines; tailor the available medications to the various presentations of IBD with attention to the induction and the maintenance of remission; and use currently available laboratory tests to maximize benefit while minimizing toxicity:

Label	Frequency	Percent	Valid Percent
Yes	32	68.09	69.57
Somewhat	13	27.66	28.26
Not at all	1	2.13	2.17
Total Valid	46	97.87	100.00
Total Missing	1	2.13	
Total	47	100.00	




Upon completion of this activity, I can now - Discuss the extent of abuse, misuse, addiction and diversion of opioid analgesics in the community; describe an approach to monitor and document a patient's progress with opioid therapy; implement strategies for early recognition and management of opioid abuse, misuse, addiction and diversion; understand opioid pharmacology and the use of analgesic equivalency tables:

Label	Frequency	Percent	Valid Percent
Yes	36	76.60	76.60
Somewhat	11	23.40	23.40
Not at all	0	0.00	0.00
Total Valid	47	100.00	100.00




Upon completion of this activity, I can now - Discuss the role of the incretin system in the pathophysiology of type 2 diabetes (T2DM); define the role of GLP-1 receptor agonist therapy in the treatment algorithm for T2DM; identify the features, benefits, and limitations of individual GLP-1 agonists; discuss the appropriate selection of GLP-1 receptor agonist therapy according to the glycemic disturbance most in need of correction:

Label	Frequency	Percent	Valid Percent
Yes	42	89.36	95.45
Somewhat	2	4.26	4.55
Not at all	0	0.00	0.00
Total Valid	44	93.62	100.00
Total Missing	3	6.38	
Total	47	100.00	




Upon completion of this activity, I can now - Use of the CHADS2 score to assess stroke risk in patients with atrial fibrillation (AF); recognize the benefits versus risks of antithrombotic therapy for stroke risk reduction in AF patients; identify safe and effective use of new and emerging antithrombotic therapy for AF patients related to the risk stratification for stroke; and identify relevant patient characteristics to guide the selection and monitoring of antithrombotic therapy in patients with atrial fibrillation:

Label	Frequency	Percent	Valid Percent
Yes	34	72.34	77.27
Somewhat	10	21.28	22.73
Not at all	0	0.00	0.00
Total Valid	44	93.62	100.00
Total Missing	3	6.38	
Total	47	100.00	




Overall, I would rate this activity as:

Label	Frequency	Percent	Valid Percent
Excellent	31	65.96	67.39
Very Good	13	27.66	28.26
Good	2	4.26	4.35
Fair	0	0.00	0.00
Poor	0	0.00	0.00
Total Valid	46	97.87	100.00
Total Missing	1	2.13	
Total	47	100.00	




Overall, this activity was effective in enhancing my confidence in caring for patients with the condition(s) presented?

Label	Frequency	Percent	Valid Percent
Strongly Agree	25	53.19	54.35
Agree	21	44.68	45.65
Neutral	0	0.00	0.00
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	46	97.87	100.00
Total Missing	1	2.13	
Total	47	100.00	




Overall, this activity was effective in improving my knowledge in the content areas presented:

Label	Frequency	Percent	Valid Percent
Strongly Agree	26	55.32	56.52
Agree	20	42.55	43.48
Neutral	0	0.00	0.00
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	46	97.87	100.00
Total Missing	1	2.13	
Total	47	100.00	




As a result of this activity, I have learned new strategies for patient care:

Label	Frequency	Percent	Valid Percent
Strongly Agree	26	55.32	56.52
Agree	18	38.30	39.13
Neutral	2	4.26	4.35
Disagree	0	0.00	0.00
Strongly Disagree	0	0.00	0.00
Total Valid	46	97.87	100.00
Total Missing	1	2.13	
Total	47	100.00	




How likely are you to implement these new strategies in your practice?

Label	Frequency	Percent	Valid Percent
Very likely	32	68.09	69.57
Somewhat likely	11	23.40	23.91
Unlikely	2	4.26	4.35
Not applicable	1	2.13	2.17
Total Valid	46	97.87	100.00
Total Missing	1	2.13	
Total	47	100.00	




When do you intend to implement these new strategies into your practice?

Label	Frequency	Percent	Valid Percent
Within 1 month	28	59.57	62.22
1-3 months	11	23.40	24.44
4-6 months	2	4.26	4.44
Not applicable	4	8.51	8.89
Total Valid	45	95.74	100.00
Total Missing	2	4.26	
Total	47	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Nelson Watts, MD (Osteo):

Label	Frequency	Percent	Valid Percent
Excellent	31	65.96	68.89
Very Good	13	27.66	28.89
Good	1	2.13	2.22
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	45	95.74	100.00
Total Missing	2	4.26	
Total	47	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Brad P. Glick, DO (Psoriasis):

Label	Frequency	Percent	Valid Percent
Excellent	26	55.32	57.78
Very Good	12	25.53	26.67
Good	5	10.64	11.11
Fair	2	4.26	4.44
Unsatisfactory	0	0.00	0.00
Total Valid	45	95.74	100.00
Total Missing	2	4.26	
Total	47	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Jordan Hopchik, CRNP (IBD):

Label	Frequency	Percent	Valid Percent
Excellent	20	42.55	44.44
Very Good	15	31.91	33.33
Good	9	19.15	20.00
Fair	1	2.13	2.22
Unsatisfactory	0	0.00	0.00
Total Valid	45	95.74	100.00
Total Missing	2	4.26	
Total	47	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Carol P. Curtiss, MSN (Opioids):

Label	Frequency	Percent	Valid Percent
Excellent	35	74.47	77.78
Very Good	7	14.89	15.56
Good	3	6.38	6.67
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	45	95.74	100.00
Total Missing	2	4.26	
Total	47	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Robert Busch, MD (Diabetes):

Label	Frequency	Percent	Valid Percent
Excellent	40	85.11	95.24
Very Good	2	4.26	4.76
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	42	89.36	100.00
Total Missing	5	10.64	
Total	47	100.00	




In terms of delivery of the presentation, please rate the effectiveness of the speaker: Kathleen Higgins, CRNP (AFib):

Label	Frequency	Percent	Valid Percent
Excellent	21	44.68	52.50
Very Good	14	29.79	35.00
Good	5	10.64	12.50
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	40	85.11	100.00
Total Missing	7	14.89	
Total	47	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Nelson Watts, MD (Osteo):

Label	Frequency	Percent	Valid Percent
Excellent	36	76.60	81.82
Very Good	5	10.64	11.36
Good	3	6.38	6.82
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	44	93.62	100.00
Total Missing	3	6.38	
Total	47	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Brad P. Glick, DO (Psoriasis):

Label	Frequency	Percent	Valid Percent
Excellent	37	78.72	82.22
Very Good	3	6.38	6.67
Good	4	8.51	8.89
Fair	0	0.00	0.00
Unsatisfactory	1	2.13	2.22
Total Valid	45	95.74	100.00
Total Missing	2	4.26	
Total	47	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Jordan Hopchik, CRNP (IBD):

Label	Frequency	Percent	Valid Percent
Excellent	36	76.60	80.00
Very Good	6	12.77	13.33
Good	3	6.38	6.67
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	45	95.74	100.00
Total Missing	2	4.26	
Total	47	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Carol P. Curtiss, MSN (Opioids):

Label	Frequency	Percent	Valid Percent
Excellent	42	89.36	93.33
Very Good	3	6.38	6.67
Good	0	0.00	0.00
Fair	0	0.00	0.00
Unsatisfactory	0	0.00	0.00
Total Valid	45	95.74	100.00
Total Missing	2	4.26	
Total	47	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Robert Busch, MD (Diabetes):

Label	Frequency	Percent	Valid Percent
Excellent	40	85.11	93.02
Very Good	1	2.13	2.33
Good	1	2.13	2.33
Fair	1	2.13	2.33
Unsatisfactory	0	0.00	0.00
Total Valid	43	91.49	100.00
Total Missing	4	8.51	
Total	47	100.00	




To what degree do you believe that the subject matter was presented fair, balanced, and free of commercial bias? Kathleen Higgins, CRNP (AFib):

Label	Frequency	Percent	Valid Percent
Excellent	34	72.34	80.95
Very Good	5	10.64	11.90
Good	1	2.13	2.38
Fair	2	4.26	4.76
Unsatisfactory	0	0.00	0.00
Total Valid	42	89.36	100.00
Total Missing	5	10.64	
Total	47	100.00	




Which statement(s) best reflects your reasons for participating in this activity:

Label	Frequency	Percent	Valid Percent
Topics covered	28	59.57	62.22
Location/ease of access	25	53.19	55.56
Faculty	4	8.51	8.89
Earn CME credits	38	80.85	84.44
Total Valid	45	95.74	100.00
Total Missing	2	4.26	
Total	47	100.00	



Future CE activities concerning this subject matter are necessary:

Label	Frequency	Percent	Valid Percent
Strongly agree	15	31.91	33.33
Agree	23	48.94	51.11
Neutral	6	12.77	13.33
Disagree	1	2.13	2.22
Strongly Disagree	0	0.00	0.00
Total Valid	45	95.74	100.00
Total Missing	2	4.26	
Total	47	100.00	



What is your professional degree?

Comment
BSN

What is your specialty?

Comment
Pediatrics
Home Health
Substance Abuse
Infectious Disease
Orthopedics
Psychiatry
Urology
Addiction
Rehab

As a result of this activity, I have learned new strategies for patient care. List these strategies:

Comment
Learned about new medications I was not aware of
New strategies for pain management and identifying potential for substance abuse. Strategies or tailoring treatment for specific patient needs on types presented at conference
Proper use of treatments for osteoporosis. Complete for patients with psoriasis, always involve GI specialist with IBD. GLP-1 agonists given better A1C reduction than DPP-4 inhibitor. Coumadin only has 1% risk of 1CH
Patient education
Expanded my knowledge on these topics to help treat my patients
Evaluation, assessment and treatment
Provided more information to help with patient education and assessment tools to monitor effectiveness
Better understanding of DPP-4 inhibitors vs. GLP-1 agonist, ordering DXA scans appropriately
Budesonide as tx for UC until can be seen by GI; adding Vit D cream to steroids for psoriasis; earlier screening with DEXA for men; begin using CHADS2 scoring guidelines more often
Improve assessment and tx of osteoporosis. Improved use of GLP-1 in diabetic therapy
Differentiation of UC/IBD/Hx questions for psoriasis risk factors/UC/IBD/ exploring what is an individuals medicine cabinet/-eval T2DM meds and incorporating new guidelines up to date guidelines - on Afib change new dx
Assessing for chronic pain, and establishing a proper treatment plan based on assessment. Establishing treatment modalities for IBD patients, ulcerative colitis vs Crohns disease
CHAD2 score for risk-this will help to determine which patients can hold anticoagulants prior to endoscopic procedures
Treatment for DM, pain management

Comment
Will use more GLP1 for diabetes. Treat psoriasis more aggressively
Incorporating Frax for assessment of BMD, choosing GLP-1 medications for diabetics. Using therapies for IBD vs Crohns
I've learned more about screening for these conditions
Use of the Frax on a regular basis, use GLP-1 medications
1. Increased screening for osteoporosis and IBD. 2. Avoidance of NSAIDs in pts with certain risk factors. 3. Increased use of GLP-1 agonists and DPP-4 inhibitor.
Availability of multi-drug therapy, Individualize plan
GLP-1 Therapy. CHAD2 and guidelines
History assessment, current recommendations
New strategies to tx diabetes patients with uncontrolled glycemic and HgA1C
Will be more aggressive in tx of psoriasis and PSA - tended to titrate MTX with add TNF. Will increase screening for OP in men, this was population missed
Use of analgesic converter online tools for pain management. Diabetic mgmt guidelines for newer meds. CHAD Score assessment
I found the lecture on diabetes quite helpful
Will use FRAX & screen for osteoporosis more consistently. Begin to use more GLP-1.
Would like more teaching by Dr Busch. I could learn a lot from him.
Lock-box for opioid medications. May start byetta/victoza GLP-1 inhibitor in practice.
will consider using dabigatran in treatment of Afib and use CHADs to risk stratify

What topics would you like to see offered as CE activities in the future?

Comment
More Pediatrics
Antiplatelets/Antithrombotics
Management of menopause with Pharm Treatment. Management of Low T with Pharm Treatment
Rheumatology
Hypertension, pediatrics, EKGs, asthma, COPD, incontinence
Hypertension, Thyroid problem, Obesity and Respiratory problems
Asthma
Emergency med topics, Psychiatry topics
MRT, STD, dermatology for primary care provider
COPD - new treatment options (several new drugs have come to market recently)
More GI
HTN, HLP, non-compliance issues, CAD, arrhythmias, EKGs, common cancers - signs, symptoms, diagnosis, testing, kidney disease, COPD, auto-immune disorders.
Depression, ekg, post MI treatment, abdominal pain
Polypharmacy
Women's health
Pediatrics acute illnesses, injuries, gout, women's health
Obesity, HTN, sleep disorders, decreasing testosterone (eval and tx)
HTN, hyperlipidemia, insulin in diabetes, dermatology in primary care, depression/anxiety diagnosis and treatment
Diabetes, Stroke, Hypertension
Thyroid disease, memory evaluation (types dementia and w/u)
How to start various types insulin, Antibiotic/Antiviral-current recommend.
Just bring back Dr. Busch
Pulmonology/Dermatology updates-broad spectrum
All treatments of AFiB

Additional comments:

Comment
Great Conference
Dr Robert Busch was the best educator of the day. He was at OUR LEVEL!!! Taught very well.
Great lectures!
Dr Busch was great!
Dr Glick, Carol Curtiss, Dr Busch, they did a great job!
Get in touch with FL PA through FAPA - next location
Please continue to offer free CME conferences
Come to Pensacola, Panama City or Tallahassee. There is a very active ARAP Practice Council in Tallahassee plus it's a college of nursing, plus ease of access for those from Alabama and Georgia.
Great clinical update - to the point, would also help to include 'clinical pearls'
Come to Destin
Thanks for a very convenient and enjoyable educational presentation.
Dr Busch gave the best diabetes I have ever attended in 11 years of practice. Great job!
Excellent CME. Dr Busch excellent. How to advance therapy for DM utilizing GLP-1
Great conference and helpful to my practice. Thanks!
Dr Busch was excellent.
Dr Busch was an excellent lecturer!
Dr Busch and Kathleen Higgins were excellent.

Item Statistics:

	Title	Specialty	Learning Objectives1	Learning Objectives2	Learning Objectives3	Learning Objectives4	Learning Objectives5
Mean	3.30	2.57	1.09	1.28	1.33	1.23	1.05
Variance	0.65	7.42	0.08	0.25	0.27	0.18	0.04
Standard Deviation	0.81	2.72	0.28	0.50	0.52	0.43	0.21
Standard Error	0.12	0.40	0.04	0.07	0.08	0.06	0.03
Minimum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Maximum	6.00	8.00	2.00	3.00	3.00	2.00	2.00
Median	3.00	1.00	1.00	1.00	1.00	1.00	1.00
Range	5.00	7.00	1.00	2.00	2.00	1.00	1.00

	Learning Objectives6	Overall Activity	Enhancing My Confidence	Improving My Knowledge	Patient Care	Make Changes	Implement New Strategies
Mean	1.23	1.37	1.46	1.43	1.48	1.39	1.60
Variance	0.18	0.33	0.25	0.25	0.34	0.47	0.88
Standard Deviation	0.42	0.57	0.50	0.50	0.59	0.68	0.94
Standard Error	0.06	0.08	0.07	0.07	0.09	0.10	0.14
Minimum	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Maximum	2.00	3.00	2.00	2.00	3.00	4.00	4.00
Median	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Range	1.00	2.00	1.00	1.00	2.00	3.00	3.00

	Nelson Watts MD {Osteo}	Brad P Glick DO {Psoriasis}	Jordan Hopchik CRNP {IBD}	Carol P Curtiss MSN {Opioids}	Robert Busch MD {Diabetes}	Kathleen Higgins CRNP {AFib}	Nelson Watts MD {Osteo} Bias
Mean	4.67	4.38	4.20	4.71	4.95	4.40	4.75
Variance	0.27	0.74	0.71	0.35	0.05	0.50	0.33
Standard Deviation	0.52	0.86	0.84	0.59	0.22	0.71	0.58
Standard Error	0.08	0.13	0.13	0.09	0.03	0.11	0.09
Minimum	3.00	2.00	2.00	3.00	4.00	3.00	3.00
Maximum	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Median	5.00	5.00	4.00	5.00	5.00	5.00	5.00
Range	2.00	3.00	3.00	2.00	1.00	2.00	2.00

	Brad P Glick DO {Psoriasis} Bias	Jordan Hopchik CRNP {IBD} Bias	Carol P Curtiss MSN {Opioids} Bias	Robert Busch MD {Diabetes} Bias	Kathleen Higgins CRNP {AFib} Bias	Reasons for Participating	Future CE Activities
Mean	4.67	4.73	4.93	4.86	4.69	-	1.84
Variance	0.68	0.34	0.06	0.31	0.56	-	0.54
Standard Deviation	0.83	0.58	0.25	0.56	0.75	-	0.74
Standard Error	0.12	0.09	0.04	0.09	0.12	-	0.11
Minimum	1.00	3.00	4.00	2.00	2.00	-	1.00
Maximum	5.00	5.00	5.00	5.00	5.00	-	4.00
Median	5.00	5.00	5.00	5.00	5.00	-	2.00
Range	4.00	2.00	1.00	3.00	3.00	-	3.00